D. Lucas

发表

Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.

Guido Marcucci, Manuela Zucknick, Lianbo Yu, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model.

Patrick D. Halley, J. Byrd, C. Castro, 2016, Small.

Proteomic profiling identifies specific histone species associated with leukemic and cancer cells

Michael A. Freitas, J. Byrd, M. Parthun, 2015, Clinical Proteomics.

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

John C Reed, Donna S Neuberg, M. Grever, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity

M. Grever, J. Liesveld, L. Pan, 2014, Leukemia.

protein tyrosine phosphatase PTPROt in leukemia AP-1 elements and TCL1 protein regulate expression of the gene encoding

J. Byrd, C. Croce, J. Datta, 2012 .

AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.

J. Byrd, C. Croce, Satavisha Roy, 2011, Blood.

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.

Thomas S. Lin, M. Grever, J. Byrd, 2007, Blood.

High‐sensitivity TFA‐free LC‐MS for profiling histones

Michael A. Freitas, J. Byrd, S. Olesik, 2011, Proteomics.

Oberlies “ Sorbicillinoid Analogs with Cytotoxic and Selective Anti-Aspergillus Activities from Scytalidium album

M. Grever, H. Raja, T. El-Elimat, 2019 .

Sorbicillinoid Analogues with Cytotoxic and Selective Anti-Aspergillus Activities from Scytalidium album

M. Grever, H. Raja, T. El-Elimat, 2014, The Journal of Antibiotics.

p135 Src Homology 2 Domain-containing Inositol 5′-Phosphatase (SHIPβ) Isoform Can Substitute for p145 SHIP in FcγRIIB1-mediated Inhibitory Signaling in B Cells*

M. Aman, K. Ravichandran, D. Lucas, 2000, The Journal of Biological Chemistry.

The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease

M. Grever, A. Kinghorn, G. Lozanski, 2014, Oncotarget.

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.

Thomas S. Lin, M. Grever, J. Byrd, 2009, Blood.

Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.

Thomas S. Lin, M. Grever, J. Byrd, 2008, Blood.

Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.

M. Grever, G. Lozanski, J. Blachly, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.

J. Byrd, B. Cheson, Sin-Ho Jung, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia

M. Caligiuri, C. Bloomfield, J. Byrd, 2017, Haematologica.

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

Lindsey T. Brinton, J. Byrd, G. Habets, 2018, Cancer discovery.

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2012, Blood.

Liquid chromatography mass spectrometry profiling of histones.

Michael A. Freitas, J. Byrd, M. Parthun, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells.

J. Byrd, D. Jarjoura, D. Lucas, 2010, Blood.

Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia

C. Bloomfield, J. Byrd, K. Mrózek, 2016, British journal of haematology.

A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors

M. Grever, J. Byrd, B. Ramaswamy, 2010, Cancer Chemotherapy and Pharmacology.

The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells

J. Byrd, D. Jarjoura, D. Lucas, 2013, Clinical Cancer Research.

Screening with monoclonal anti‐Fy3 to provide blood for phenotype‐ matched transfusions for patients with sickle cell disease

D. Lucas, S. Sandler, D. Mallory, 1997, Transfusion.

Involvement of RhoH GTPase in the Development of B-Cell Chronic Lymphocytic Leukemia

David A. Williams, J. Byrd, A. Sánchez-Aguilera, 2009, Leukemia.

Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.

M. Grever, J. Byrd, T. Shanafelt, 2006, Leukemia research.

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.

Michael A. Freitas, Jeffrey A Jones, J. Byrd, 2012, Cancer cell.

development tool for human chronic lymphocytic leukemia Characterization of the TCL-1 transgenic mouse as a preclinical drug

Lisa L. Smith, M. Grever, J. Byrd, 2013 .

Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.

Lisa L. Smith, M. Grever, J. Byrd, 2006, Blood.

UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.

M. Grever, J. Byrd, I. Flinn, 2001, Experimental hematology.

Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation.

J. Armitage, M. Grever, J. Byrd, 2003, Transplantation.

Pentostatin in steroid-refractory acute graft-versus-host disease.

M. Grever, J. Byrd, J. Bolaños-Meade, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.

M. Grever, J. Byrd, A. Johnson, 2007, Best practice & research. Clinical haematology.

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.

M. Caligiuri, M. Grever, J. Byrd, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRAF V600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia

M. Grever, J. Byrd, G. Lozanski, 2017 .

Therapeutic Potential of the Translation Inhibitor Silvestrol in Hepatocellular Cancer

M. Grever, T. Patel, I. Yan, 2013, PloS one.

Quantitative profiling of histone post-translational modifications by stable isotope labeling.

Michael A. Freitas, J. Byrd, M. Parthun, 2007, Methods.

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

J. Byrd, S. Kambhampati, K. Blum, 2009, British journal of haematology.

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Lisa L. Smith, M. Grever, J. Byrd, 2004, Blood.

Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia

M. Caligiuri, M. Grever, J. Byrd, 2013, Journal of Hematology & Oncology.

Phase II study of the histone deacetylase inhibitor MGCD 0103 in patients with previously treated chronic lymphocytic leukaemia

Marja, J. Byrd, K. Blum, 2009 .

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Jeffrey A Jones, Emanuela M. Ghia, Lisa L. Smith, 2014, Blood.

high-risk chronic lymphocytic leukemia associated with marked clinical efficacy in refractory, genetically Flavopiridol administered using a pharmacologically derived schedule is

M. Grever, B. Rovin, N. Heerema, 2013 .

Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias

M. Grever, J. Byrd, B. Rovin, 2010, Haematologica.

Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: dose‐limiting myelosuppression without evidence of DNA hypomethylation

Jeffrey A Jones, M. Grever, J. Byrd, 2010, British journal of haematology.

NF-κB p50 (nfkb1) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia.

J. Byrd, A. Johnson, D. Lucas, 2017, Blood.

Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol

M. Grever, A. Kinghorn, D. Jarjoura, 2012, Clinical Cancer Research.

Rituximab and 17‐allylamino‐17‐demethoxygeldanamycin induce synergistic apoptosis in B‐cell chronic lymphocytic leukaemia

Lisa L. Smith, M. Grever, J. Byrd, 2007, British journal of haematology.

Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia

J. Byrd, L. Naumovski, P. Lecane, 2009, Leukemia & lymphoma.

Motexafin Gadolinium Induces Apoptosis in Lymphoid Cell Lines and Demonstrates Enhanced Biological Activity with Akt Kinase Inhibitors.

J. Byrd, L. Naumovski, Jun Chen, 2004 .

intracellular calcium leukemia cells with impaired oxygen consumption and mobilization of Flavopiridol causes early mitochondrial damage in chronic lymphocytic

M. Grever, J. Byrd, A. Johnson, 2013 .

with p53 mutations and deletions Alemtuzumab is an effective therapy for chronic lymphocytic leukemia

Lisa L. Smith, M. Grever, J. Byrd, 2013 .

Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab

I. Flinn, D. Lucas, R. Ambinder, 2007, Clinical Cancer Research.

Mitochondria control of cell death induced by anti-HLA-DR antibodies

J. Byrd, D. Lucas, J. Tso, 2003, Leukemia.

Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells

M. Grever, J. Byrd, N. Heerema, 2011, The AAPS Journal.

Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines

Hiroki Sato, K. Goi, Y. Furukawa, 2017, PloS one.

Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Jeffrey S. Johnston, M. Grever, C. Hofmeister, 2013, Clinical Pharmacokinetics.

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia

M. Grever, J. Byrd, I. Flinn, 2005, Leukemia.

Methylation and Silencing of Protein Tyrosine Phosphatase Receptor Type O in Chronic Lymphocytic Leukemia

M. Grever, J. Byrd, D. Neuberg, 2007, Clinical Cancer Research.

Methylation and Silencingof Protein Tyrosine Phosphatase Receptor Type O in Chronic Lymphocytic Leukemia

M. Grever, J. Byrd, D. Neuberg, 2007 .

Cardiac Glycoside Constituents of Streblus asper with Potential Antineoplastic Activity.

A. Kinghorn, Wei-Lun Chen, Xiaozhuo Chen, 2017, Journal of natural products.

Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species.

A. Kinghorn, D. Lucas, J. Woodard, 2014, Natural product reports.

Potential of plant-derived natural products in the treatment of leukemia and lymphoma.

M. Grever, D. Lucas, A. Kinghorn, 2010, Current drug targets.

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.

Derek A. West, M. Grever, J. Byrd, 2009, Blood.

Characterization of Silvestrol Pharmacokinetics in Mice Using Liquid Chromatography–Tandem Mass Spectrometry

M. Grever, G. Marcucci, M. Phelps, 2011, The AAPS Journal.

Discovery of Anticancer Agents of Diverse Natural Origin.

Xiaoli Zhang, Nicholas H Oberlies, Brent R Stockwell, 2016, Anticancer research.

KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.

M. Grever, J. Byrd, D. Lucas, 2003, Blood.

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997

M. Grever, J. Byrd, J. Gribben, 2015, Leukemia & lymphoma.

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.

Andrew W. Greaves, M. Grever, J. Byrd, 2014, Blood.

TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.

M. Grever, J. Byrd, C. Plass, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study

J. Byrd, J. Gribben, R. Larson, 2012, Leukemia & lymphoma.

response to therapy distinct molecular characteristics and does not indicate a suboptimal Prolonged lymphocytosis during ibrutinib therapy is associated with

Jeffrey A Jones, Emanuela M. Ghia, Lisa L. Smith, 2014 .

Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies

J. Byrd, R. Garzon, Y. Chook, 2015, Leukemia.

Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity

M. Caligiuri, M. Grever, J. Byrd, 2007, Clinical Cancer Research.

Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma

Jeffrey A Jones, J. Byrd, F. Awan, 2015, Leukemia & lymphoma.

Downregulation of Death-Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia

D. Weisenburger, M. Grever, J. Byrd, 2007, Cell.

Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets

Lisa L. Smith, J. Byrd, C. Plass, 2004, Cancer Research.

PTPROt Inactivates the Oncogenic Fusion Protein BCR/ABL and Suppresses Transformation of K562 Cells*

K. Ghoshal, Satavisha Roy, J. Datta, 2009, Journal of Biological Chemistry.

p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.

Kirby D. Johnson, E. Ranheim, Xuehua Zhong, 2017, Blood.

Validation of an LC‐MS based approach for profiling histones in chronic lymphocytic leukemia

Philip R. O. Payne, Michael A. Freitas, M. Grever, 2009, Proteomics.

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

M. Grever, J. Byrd, M. Parthun, 2004, Blood.

Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.

M. Grever, J. Byrd, John Calvin Reed, 2003, Blood.

Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.

Derek A. West, J. Byrd, J. Qian, 2011, Blood.

Cloning of the genomic locus of mouse SH2 containing inositol 5-phosphatase (SHIP) and a novel 110-kDa splice isoform, SHIPdelta.

D. Lucas, L. Rohrschneider, I. Wolf, 2000, Genomics.

Structure, function, and biology of SHIP proteins.

D. Lucas, Yan Liu, L. Rohrschneider, 2000, Genes & development.

A novel spliced form of SH2-containing inositol phosphatase is expressed during myeloid development.

D. Lucas, L. Rohrschneider, 1999, Blood.

in chronic lymphocytic leukemia Selective inhibitors of nuclear export show that CRM1/XPO1 is a target

J. Byrd, A. Johnson, D. Lucas, 2013 .

cyclophosphamide, and rituximab lymphocytic leukemia patients treated with pentostatin, Mcl-1 expression predicts progression-free survival in chronic

M. Grever, J. Byrd, N. Heerema, 2013 .

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Yuh Min Chook, David Lucas, J. Byrd, 2012, Blood.

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.

J. Byrd, I. Flinn, John Calvin Reed, 2002, Blood.

Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia

Jeffery A. Jones, J. Byrd, C. Plass, 2016, Oncotarget.

The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells

M. Grever, J. Byrd, John Calvin Reed, 2004, Leukemia.

Plenary paper Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

M. Grever, J. Byrd, B. Rovin, 2006 .

BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation.

M. Grever, J. Byrd, G. Lozanski, 2015, Leukemia research.

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma

Lisa L. Smith, J. Byrd, A. Johnson, 2009, Leukemia & lymphoma.

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma

Lisa L. Smith, J. Byrd, A. Johnson, 2009 .

Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective

Jeffrey A Jones, M. Grever, J. Byrd, 2015, Haematologica.

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.

M. Caligiuri, C. Bloomfield, M. Grever, 2003, Blood.

Comprehensive single nucleotide polymorphism study supports the role of MDM2 in p53-competent chronic lymphocytic leukemia.

J. Byrd, D. Lucas, 2008, Journal of Clinical Oncology.

The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia

M. Grever, K. Coombes, I. Flinn, 2017, OncoTarget.

Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma

Jeffrey S. Johnston, J. Byrd, A. Ferketich, 2009, mAbs.

Transducin b-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma

J. Byrd, G. Nuovo, K. Young, 2020, Haematologica.

Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry.

Michael A. Freitas, J. Byrd, M. Parthun, 2007, Analytical biochemistry.

A Phase I/II Study of Etanercept and Rituximab in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

M. Caligiuri, J. Byrd, N. Heerema, 2009, Leukemia.

Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia.

Jeffrey A Jones, M. Grever, G. Lozanski, 2021, Blood.

Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.

M. Caligiuri, G. Lozanski, K. Heider, 2016, Blood.

Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

M. Grever, J. Byrd, E. Kraut, 2004 .

Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).

M. Grever, J. Byrd, K. Blum, 2004 .

BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia.

M. Grever, J. Byrd, G. Lozanski, 2016, Blood advances.

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors

J. Byrd, G. Lozanski, C. Brooks, 2018, Haematologica.

Differential utilization of IFN-gamma-responsive elements in two maturationally distinct macrophage cell lines.

D. Lucas, C. Nicolet, M. McDowell, 1995, Journal of immunology.

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

Derek A. West, Michael A. Freitas, M. Grever, 2010, PloS one.

Increasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis

Michael A. Freitas, J. Byrd, M. Parthun, 2013, Nucleic acids research.

Analysis of the IFN-γ-Signaling Pathway in Macrophages at Different Stages of Maturation

D. Lucas, M. Lokuta, M. McDowell, 1998, The Journal of Immunology.

Analysis of the IFN-gamma-signaling pathway in macrophages at different stages of maturation.

D. Lucas, M. Lokuta, M. McDowell, 1998, Journal of immunology.

Analysis of the IFN-g-Signaling Pathway in Macrophages at Different Stages of Maturation1

D. Lucas, M. Lokuta, M. McDowell, 1998 .

Proteomic profiling identifies specific histone species associated with leukemic and cancer cells

Michael A. Freitas, J. Byrd, M. Parthun, 2015, Clinical Proteomics.

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia

Jeffrey A Jones, M. Grever, G. Lozanski, 2018, Leukemia & lymphoma.

Potentiating Effect of the Flavonolignan (‐)‐Hydnocarpin in Combination with Vincristine in a Sensitive and P‐gp‐Expressing Acute Lymphoblastic Leukemia Cell Line

D. Lucas, A. Kinghorn, Li Pan, 2013, Phytotherapy research : PTR.

The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2009 .

Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment

M. Grever, G. Lozanski, J. Blachly, 2018, Blood.

Bioactive constituents of Indigofera spicata.

A. Kinghorn, D. Lantvit, D. Lucas, 2013, Journal of natural products.

Second malignancies in B‐cell chronic lymphocytic leukaemia: possible association with human papilloma virus

J. Byrd, L. Andritsos, J. Flynn, 2010, British journal of haematology.

G3139, a BCL-2 antisense oligo-nucleotide, in AML.

M. Caligiuri, M. Grever, J. Byrd, 2004, Annals of hematology.

Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997

M. Grever, J. Byrd, J. Gribben, 2010 .

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.

M. Caligiuri, M. Grever, J. Byrd, 2006 .

The Novel Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Potent Cytotoxicity in Primary Chronic Lymphocytic Leukemia Cells and a Defective NF-κB Response,

J. Byrd, D. Lucas, Melanie E. Davis, 2011 .